Ken Griffin Harmony Biosciences Holdings, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 28,400 shares of HRMY stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,400

Previous 6,200 358.06%

Holding current value

$1.01 Million

Previous $205,000 337.56%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$32.18 - $40.46 $16.3 Million - $20.5 Million	-505,826 Reduced 36.97%	862,406 $28.6 Million
Q4 2024 Feb 14, 2025	BUY	$31.86 - $41.49 $38.7 Million - $50.4 Million	1,213,556 Added 784.58%	1,368,232 $47.1 Million
Q3 2024 Nov 14, 2024	SELL	$30.0 - $39.95 $15.9 Million - $21.2 Million	-529,642 Reduced 77.4%	154,676 $6.18 Million
Q2 2024 Aug 14, 2024	BUY	$28.81 - $33.01 $2.96 Million - $3.39 Million	102,698 Added 17.66%	684,318 $20.6 Million
Q1 2024 May 15, 2024	BUY	$29.93 - $35.06 $15.1 Million - $17.6 Million	502,887 Added 638.72%	581,620 $19.5 Million
Q4 2023 Feb 14, 2024	SELL	$19.2 - $33.78 $3.14 Million - $5.52 Million	-163,347 Reduced 67.48%	78,733 $2.54 Million
Q3 2023 Nov 14, 2023	SELL	$31.89 - $39.03 $17.8 Million - $21.8 Million	-558,780 Reduced 69.77%	242,080 $7.93 Million
Q2 2023 Aug 14, 2023	BUY	$30.5 - $37.4 $8.21 Million - $10.1 Million	269,053 Added 50.59%	800,860 $28.2 Million
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $12.2 Million - $21.3 Million	395,854 Added 291.17%	531,807 $17.4 Million
Q4 2022 Feb 14, 2023	SELL	$45.4 - $60.91 $374,550 - $502,507	-8,250 Reduced 5.72%	135,953 $7.49 Million
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $2.98 Million - $3.92 Million	70,740 Added 96.29%	144,203 $6.39 Million
Q2 2022 Aug 15, 2022	SELL	$33.54 - $52.15 $3.19 Million - $4.96 Million	-95,016 Reduced 56.4%	73,463 $3.58 Million
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $2.59 Million - $3.99 Million	78,048 Added 86.31%	168,479 $8.2 Million
Q4 2021 Feb 14, 2022	BUY	$34.09 - $43.91 $1.68 Million - $2.17 Million	49,384 Added 120.31%	90,431 $3.86 Million
Q3 2021 Nov 15, 2021	SELL	$25.68 - $38.61 $95,632 - $143,783	-3,724 Reduced 8.32%	41,047 $1.57 Million
Q2 2021 Aug 16, 2021	SELL	$25.96 - $33.44 $155,967 - $200,907	-6,008 Reduced 11.83%	44,771 $1.26 Million
Q1 2021 May 17, 2021	BUY	$27.56 - $40.37 $639,281 - $936,422	23,196 Added 84.1%	50,779 $1.68 Million
Q4 2020 Feb 16, 2021	SELL	$31.74 - $51.34 $6.09 Million - $9.86 Million	-192,010 Reduced 87.44%	27,583 $997,000
Q3 2020 Nov 16, 2020	BUY	$30.96 - $44.39 $6.8 Million - $9.75 Million	219,593 New	219,593 $7.45 Million

Others Institutions Holding HRMY

# of Institutions

288

Shares Held

46.2M

Call Options Held

316K

Put Options Held

69.9K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.1B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account